Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
6605 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2025-01-23 (pharmaphorum.com)
US/EU regulators start review of Biogen's high-dose Spinraza |
Biogen's new high-dose version of SMA drug Spinraza has started regulatory reviews, but can it help return the drug to growth?
Read more
2024-11-21 (fuldaerzeitung.de)
EU gives green light for Alzheimer's therapy with antibodies
More and more people are suffering from Alzheimer's. The antibody lecanemab, whose approval the EU recently recommended, could help some of these.
Read more
2024-11-16 (srf.ch)
EU approves Alzheimer's drug Leqembi
The EU recommends approval of an Alzheimer's drug that slows down the progression of the disease. How does it work?
Read more
2024-11-15 (shz.de)
Dementia: First Alzheimer's therapy recommended for approval in the EU
The EU Medicines Agency has given the green light to Alzheimer's therapy in the EU that targets the underlying disease processes.
Read more
2024-11-15 (devdiscourse.com)
EU Reverses Course: Approval for Breakthrough Alzheimer's Drug Leqembi Recommended
The EU's drugs regulator has recommended approval for Leqembi, a treatment by Eisai and Biogen, for early Alzheimer's disease. This could position it as the EU’s first treatment for the condition.
Read more
2024-11-15 (devdiscourse.com)
EU Backs Leqembi: A Breakthrough in Alzheimer's Treatment
The European Union's drugs regulator has recommended approval for Eisai and Biogen's Alzheimer's drug Leqembi. This marks a potential first treatment approval in the EU for early Alzheimer's, focusing on patients without the ApoE4 gene variant.
Read more
2024-11-15 (thehindu.com)
EU regulator backs Eisai-Biogen Alzheimer’s drug
EU drugs regulator recommends approval of Leqembi for early Alzheimer's, pending European Commission acceptance, for specific patient group.
Read more
2024-10-02 (euractiv.com)
Alzheimer’s drug lecanemab, EMA re-examining marketing authorisation
The European Medicines Agency’s human medicines committee is re-examining the marketing authorisation application for the Alzheimer’s disease (AD) drug lecanemab, a treatment that has been shown to slow cognitive decline.
Read more
2024-09-22 (investing.com)
Biosimilars from Samsung Bioepis and Biogen near EU approval By Investing.com
Biosimilars from Samsung Bioepis and Biogen near EU approval
Read more
2024-07-31 (pharmaphorum.com)
After EU setback, Eisai/Biogen build case for Leqembi
Eisai, Biogen report data showing benefit of Alzheimer's disease therapy Leqembi builds with time, with no increase in safety risk.
Read more
2024-07-29 (investing.com)
Eisai shares fall 13% after EU authorities reject Alzheimer's drug made with Biogen By Investing.com
Eisai shares fall 13% after EU authorities refuse Alzheimer's drug made with Biogen
Read more
2024-07-27 (proinvestor.com)
BioArctic falls heavily
It is my impression, after hearing interviews with their CEO, that EMA's decision has come as a great shock. But another good example of never feeling safe before
Read more